Emily Craig Zabor

Emily Craig Zabor

Auto-generated profile, based on publicly available information

Emily Craig Zabor

Department of Quantitative Health Sciences Cleveland Clinic Research Cleveland Ohio USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Chest
Verified
Journal Article
Closed access
EZEmily C. Zabor
Emily C. Zabor
AKAlexander M. Kaizer
Alexander M. Kaizer
BHBrian P. Hobbs
Brian P. Hobbs

1 August 2013 in Cancer
Verified
Journal Article
Open access
PDF file
EZEmily C. Zabor
Emily C. Zabor
MGMithat Gonen
Mithat Gonen
PCPaul B. Chapman
Paul B. Chapman
KPKatherine S. Panageas
Katherine S. Panageas
Measures of prognosis are typically estimated from the time of diagnosis. However, these estimates become less relevant as the time from diagnosis increases for a patient. Conditional survival measures the probability that a cancer patient will survive some additional number of years, given that the patient has already survived for a certain number of years. In the current study, the authors analyzed data regarding patients with stage III melanoma to demonstrate that survival estimates from the time of diagnosis underestimate long‐term survival as the patient is followed over time. The probability of surviving to year 5 for patients at the time of presentation compared with patients who had already survived for 4 years increased from 72% to 95%, 48% to 90%, and 29% to 86%, respectively, for patients with substage IIIA, IIIB, and IIIC disease. Considering the major role played by survival estimates during follow‐up in patient counseling and the development of survivorship programs, the authors strongly recommend the routine use of conditional survival estimates. Cancer 2013;119:3589–3592. © 2013 American Cancer Society.

20 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BHBrian P. Hobbs
Brian P. Hobbs
RPRoberto Carmagnani Pestana
Roberto Carmagnani Pestana
EZEmily C. Zabor
Emily C. Zabor
AKAlexander M. Kaizer
Alexander M. Kaizer
DHDavid S. Hong
David S. Hong
Advances in biology and immunology have elucidated genetic and immunologic origins of cancer. Innovations in sequencing technologies revealed that distinct cancer histologies shared common genetic and immune phenotypic traits. Pharmacologic developments made it possible to target these alterations, yielding novel classes of targeted agents whose therapeutic potential span multiple tumor types. Basket trials, one type of master protocol, emerged as a tool for evaluating biomarker-targeted therapies among multiple tumor histologies. Conventionally conducted within the phase II setting and designed to estimate high and durable objective responses, basket trials pose challenges to statistical design and interpretation of results. This article reviews basket trials implemented in oncology studies and discusses issues related to their statistical design and analysis.

10 May 2019
Verified
Dataset
Closed access
DSDaniel D. Sjoberg
Daniel D. Sjoberg
JLJoseph Larmarange
Joseph Larmarange
MCMichael Curry
Michael Curry
EREmily de la Rua
Emily de la Rua
JLJessica Lavery
Jessica Lavery
EZEmily C. Zabor
Emily C. Zabor

30 October 2025 in Blood
Verified
Journal Article
Closed access
TBTaylor R. Brooks
Taylor R. Brooks
EZEmily C. Zabor
Emily C. Zabor
YBYohanna B. Bedelu
Yohanna B. Bedelu
XYXi Yang
Xi Yang
YKYasmin Karimi
Yasmin Karimi
BHBrian T. Hill
Brian T. Hill
Epcoritamab and glofitamab are CD20-directed bispecific antibodies (BsAbs) approved in the United States for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Limited data exist for patients treated outside of trials. Patients with R/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collected from 21 United States institutions. Among 245 patients, 156 received epcoritamab and 89 received glofitamab, 113 were refractory to front-line therapy, 40 had MYC and BCL2 and/or BCL6 rearrangements, 147 received prior chimeric antigen receptor T-cell therapy, and 174 patients would have been ineligible for registrational trials. The overall response rate (ORR) for epcoritamab and glofitamab was 51% (23% complete response, [CR]) and 53% (30% CR), respectively. Median progression-free survival (PFS) was 2.6 months (95% confidence interval [CI], 2.0-3.8 months), and median overall survival (OS) was 7.8 months (95% CI, 6.2-11.0 months). The 6-month PFS was 36% (95% CI, 30-44) and the 6-month OS was 60% (95% CI, 54-67). Both trial ineligibility and undetectable CD20 pre-BsAbs portended shorter PFS and OS. Of 17 individuals with paired biopsies, 15 (88.2%) lost CD20 expression after BsAbs with a median time to progression of 3.7 months. This analysis including patients with R/R DLBCL shows the ORR to CD3/CD20 BsAbs was comparable to pivotal trials, although PFS and OS were lower. Baseline undetectable levels of CD20 were associated with poor outcomes. These results demonstrate the activity of BsAbs in R/R DLBCL, and underscore the importance of target antigen expression.

1 April 2018 in Journal of Urology
Verified
Journal Article
Closed access
EZEmily C. Zabor
Emily C. Zabor
HFHelena Furberg
Helena Furberg
BLByron H Lee
Byron H Lee
SCSteven Campbell
Steven Campbell
BLBrian R. Lane
Brian R. Lane
PRPaul Russo
Paul Russo
We sought to confirm the findings from a previous single institution study of 572 patients from Memorial Sloan Kettering Cancer Center in which we found that 49% of patients recovered to the preoperative estimated glomerular filtration rate within 2 years following radical nephrectomy for renal cell carcinoma. A multicenter retrospective study was performed in 1,928 patients using data contributed from 3 independent centers. The outcome of interest was postoperative recovery to the preoperative estimated glomerular filtration rate. Data were analyzed using cumulative incidence and competing risks regression with death from any cause treated as a competing event. This study demonstrated that 45% of patients had recovered to the preoperative estimated glomerular filtration rate by 2 years following radical nephrectomy. Furthermore, this study confirmed that recovery of renal function differed according to preoperative renal function such that patients with a lower preoperative estimated glomerular filtration rate had an increased chance of recovery. This study also suggested that larger tumor size and female gender were significantly associated with an increased chance of renal function recovery. In this multicenter retrospective study we confirmed that in the long term a large proportion of patients recover to preoperative renal function following radical nephrectomy for kidney tumors. Recovery is more likely among those with a lower preoperative estimated glomerular filtration rate.